Scarica l'app Stockscreener
1.13
0.89%
0.010
Dopo l'orario di chiusura:
1.10
-0.03
-2.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
Commonwealth Equity Services LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Aclaris Therapeutics Inc (ACRS) Has Recovered 21.49% From Its Low: Is This The Beginning Of A Trend? - stocksregister.com
Raymond James Financial Inc. Acquires Shares of 154,351 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings - The AM Reporter
Aclaris Therapeutics ATM - Leerink Partners
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald - Defense World
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com South Africa
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN
Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com
Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St
Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World
Aclaris Therapeutics plans $300M mixed shelf offering - MSN
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire
Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register
Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat
Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):